Protagonist Therapeutics PTGX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $193.71M+50.9% | $128.39M+12.9% | $113.71M-32.5% | $168.54M+20.7% | $139.65M+43.6% | ||
| $354.07M-19.3% | $438.97M-5.1% | $462.4M+15.0% | $401.92M-7.5% | $434.71M+35.1% | ||
| $613.46M+6.2% | $577.57M-1.5% | $586.42M-2.7% | $602.53M-0.6% | $605.86M+2.4% | ||
| $3.78M-2.1% | $3.86M-5.9% | $4.1M-0.2% | $4.11M+16.4% | $3.53M+10.7% | ||
| $697.46M+4.4% | $668.19M-4.8% | $701.69M-2.3% | $718.01M-3.3% | $742.13M-0.3% | ||
| $6.28M-34.2% | $9.55M+243% | $2.79M— | —— | —— | ||
| $34.55M-24.0% | $45.44M+1.1% | $44.94M+26.6% | $35.51M+1.1% | $35.11M-25.9% | ||
| $41.99M-21.5% | $53.48M-4.9% | $56.25M+12.5% | $49.99M-5.8% | $53.08M-23.5% | ||
| $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | ||
| -$466.89M+0.8% | -$470.67M-10.4% | -$426.29M-10.2% | -$386.95M-9.9% | -$352.18M-3.4% | ||
| $655.47M+6.6% | $614.71M-4.8% | $645.44M-3.4% | $668.02M-3.1% | $689.05M+2.0% | ||
| $697.46M+4.4% | $668.19M-4.8% | $701.69M-2.3% | $718.01M-3.3% | $742.13M-0.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Protagonist Therapeutics's total assets?
- Protagonist Therapeutics (PTGX) holds $697.5M in total assets, down 6.0% year over year.
- How much debt does Protagonist Therapeutics have?
- Protagonist Therapeutics carries $9.8M in total debt against $655.5M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does Protagonist Therapeutics have?
- Protagonist Therapeutics holds $193.7M in cash and equivalents.
- Can Protagonist Therapeutics cover its short-term obligations?
- Its current ratio is 17.76 — current assets exceed current liabilities.
- Where does Protagonist Therapeutics's balance sheet data come from?
- Every line is extracted from Protagonist Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
